Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing
Humacyte, Inc. (HUMA) ended the recent trading session at $0.84, demonstrating a +2.66% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.02% ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host ...
Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion –– Seasoned medtech ...
Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program evaluating the company’s acellular tissue engineered vessel (ATEV) as an ...
Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why
Humacyte, Inc. (HUMA) closed at $0.70 in the latest trading session, marking a -1.14% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.8%. Meanwhile, the Dow ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Fresenius Medical Care and Humacyte have amended their international rights agreement for Symvess, an acellular tissue engineered vessel. The revised deal realigns ex U.S. distribution rights, ...
(RTTNews) - Humacyte, Inc. (HUMA) has launched Symvess, a bioengineered vascular conduit for adults needing urgent revascularization due to extremity arterial injury when autologous vein grafts aren't ...
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed ...
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial ...
On April 21, 2026, Humacyte entered a third amendment to its distribution agreement with Fresenius Medical Care, regaining sole global rights to develop, commercialize and manage regulatory matters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results